Skip to main content

Home/ Health affairs/ Group items tagged What-is-pharmaceutical-marketing

Rss Feed Group items tagged

pharmacybiz

How Pharma Industry Can Boost Its Marketing - 0 views

  •  
    In a rapidly evolving and competitive landscape, the pharmaceutical industry faces unique challenges when it comes to marketing its products and services. With stringent regulations, complex target audiences, and a need for trust and credibility, pharma companies need to employ effective marketing strategies to stand out in the crowd. In this blog article, we will explore some key marketing strategies for the pharma industry that can help boost their visibility, engage their target audience, and drive business growth. UNDERSTANDING THE UNIQUE LANDSCAPE The pharma industry operates in a highly regulated environment, where compliance and ethical considerations play a crucial role. Before diving into marketing strategies, it is essential to have a deep understanding of the industry's dynamics and the target audience. Researching the market, identifying patient needs, and studying the competitive landscape are vital steps in developing an effective marketing plan. EMBRACING DIGITAL TRANSFORMATION Digital transformation has revolutionized marketing across industries, and the pharma sector is no exception. Embracing digital channels and technologies can significantly enhance the reach and impact of marketing efforts. Pharma companies can leverage social media platforms, create engaging content, and build online communities to connect with patients, healthcare professionals, and other stakeholders. Implementing robust digital marketing strategies allows for personalized messaging, real-time communication, and targeted campaigns that resonate with the target audience.
pharmacybiz

Build a Strong Pharma Brand: Innovative Tactics & Tips - 0 views

  •  
    Today, pharmaceutical companies can't simply make an effective drug and count on healthcare providers (HCPs) to come to them - they have to find innovative ways to attract them. Statista shows that in 2015 there were only 3,286 pharma companies with active research and development pipelines. In 2023, this number jumped to more than 5,500. As an earth-shattering number of new drugs are flooding the market each year, HCPs are having a hard time determining the best medicine for their patients. Meanwhile, pharma companies invest more in marketing to help HCPs get rid of choice paralysis and make them choose their solution over that of competitors. In this article, we will share the tried-and-true tactics to build a strong pharma brand. Get creative with interactive email marketing One…two…three…No, we're not counting to run a marathon. Three seconds is what you've got to pull your reader in with your email. Fail to quickly grab the audience's attention? We've got some bad news for you. Nobody's going to bother reading about how amazing your pharmaceutical product is if you're churning out generic emails with artificial intelligence tools.
pharmacybiz

Brain Chambers : AAH appoints as Chief Commercial Officer - 0 views

  •  
    AAH Pharmaceuticals (AAH) has announced the appointment of Brain Chambers as Chief Commercial Officer. "I'm proud to lead the commercial functions in AAH in my new role and broader area of responsibility." Said Brian. "I'm committed to delivering on great value for our customers and building and strengthening our supplier partnerships." Brain is associated with AAH Pharmaceuticals for more than 14 years. He joined the organisation as Business Development Manager in October 2008. His previous role in the organisation was on Sales and Marketing Director. He posted on LinkedIn: "This is a big move for me personally, but that's a side hustle. What is the main play here is AAH becoming a standalone independent wholesale business focussed on only the AAH customer and our core business and this is just one part of that.
pharmacybiz

PSNC 2023 Pharmacy Pressures Survey|Pharmacy Crisis UK - 0 views

  •  
    What will it take to get help from the government before an individual or sector breaks? Pharmacists raised questions after the Pharmaceutical Services Negotiating Committee (PSNC)'s 2023 Pharmacy Pressures Survey confirmed the ongoing pressures and health issues faced by the pharmacies. Pharmacists are not all shocked by the PSNC's survey report as they feel the same as what has been reported related to their businesses and health. They hope the government listens and work with them to find resolutions. "We are bullied into a corner," said Salim Jetha Chairman, Avicenna. "Unlike other industries, we can't increase our prices. Most of the daily calls I get from Independents is about financial health of their business and any cost cutting would be detrimental to patient care. Urgent holistic review is required." Bristol pharmacist Ade Williams said: "The report is a dire indictment, and I would also warn, likely an underestimate of the extent and detrimental impact of the ongoings pressures and squeeze on Community pharmacies." "If the closest interface of the NHS to communities and patients is so distressed, what does that mean for those that need and depend on us? We are notoriously very stoic, so this is a warning light, which, taken with workforce pressures, market-exit activity, and other reports raising concern about wellbeing and stress, must beg the question; what will it take to get help before the sector and individuals break?" he questioned. The survey results don't surprise Kent-based community pharmacist Amish Patel. He said, "I have been feeling exactly what has been reported for far too long. I'm burnt out and would say beginning to suffer with my own health because of it. Now it's for PSNC to talk to government, and government to listen and work with us to find resolutions."
pharmacybiz

Haleon : Raising the bar for patient care - 0 views

  •  
    Global consumer healthcare company Haleon has launched a new centre of excellence for a global leader in consumer health which will bring together world leading academics in human behaviour and frontline healthcare professionals including community pharmacists. Unveiled at the International Pharmaceutical Federation (FIP) Congress in 'sunny' Seville, Spain on September 20, the Centre will operate as a community of healthcare professionals and specialists in behavioural science, health psychology and the social sciences to solve some of the most pressing everyday health challenges. Named the Centre for Human Sciences (CHS) the initiative will be the first major programme for healthcare professionals since the Haleon's launch on July 18 as an independent, global leader in consumer health. The Centre's mission is to support practising health professionals - pharmacists, pharmacy assistants and dental professionals - in serving their patients and communities. Combining science with deep human understanding, CHS will bring expertise in physiology together with human sciences to deliver real world-solutions and tangible interventions, resulting in measurable improvements in health outcomes through sustained behavioural change. The Centre is facilitated by Robert Horne, professor of Behavioural Medicine at UCL School of Pharmacy, who started his career as a practising pharmacist but later chose to become a behavioural scientist when he saw an opportunity to address issues around psycho-social factors that acted as a hindrance in pharmacy practice. Speaking to me in an exclusive three-way conversation alongside Tess Player, the global head of healthcare professional & health influencer marketing at Haleon, on the sidelines of the FIP Congress 2022, Prof Horne expanded on what the Centre was all about and how it would work. "We've got some good ideas, but it's not a pre-filled prescription that we're going to deliver at scale from the start. What Haleon is t
pharmacybiz

Windsor Framework UK : A new way forward - 0 views

  •  
    Northern Ireland will see changes in the regulatory landscape following the issuance of the Windsor Framework on 27th Feb 2023 and the corresponding EU Commission proposal. An agreement, in principle, has been reached by the UK and EU. The new path forward of the Windsor Framework marks a turning point in how both the UK and the EU will work together collaboratively and constructively to ensure that the same medicines are available in Northern Ireland at the same time as they are in the rest of the United Kingdom. Whilst this is a successful result for Northern Ireland patients, this is major change for companies that have made specific provisions in their supply chains for Northern Ireland. The supply chains of companies where provisions and changes were made such as introduction of GB specific pack may be impacted as a result. However, the burden on the UK Pharma supply chain will be eased. Prime Minister Rishi Sunak walks with European Commission chief Ursula von der Leyen in Windsor on February 27, 2023 Pharma companies will need to carefully consider making changes within their processes and supply chains pending the issuance of clear guidance from the MHRA on the regulation changes resulting from the Windsor Agreement and the corresponding EU Commission proposed regulatory changes associated with medicinal products within the Northern Ireland market. Smooth access to the EU market for Northern Ireland pharmaceutical and medical technology firms has been safeguarded within the constraints of the agreement. The pragmatic dual-regulatory system protects business, patients and healthcare services, and reflects that it is an essential state function to maintain and oversee the supply of medicines within the whole United Kingdom.
pharmacybiz

Acepiro : Kelso Pharma launches its first product - 0 views

  •  
    Kelso Pharma, the growing UK based specialty pharma business, has announced its first product launch with the release to the UK prescription medicines market of Acepiro (Acetylcysteine) 600mg effervescent tablets. Acepiro 600 mg effervescent tablets are indicated in adults only and are being made available to hospital and community prescribers in 20 and 30 day packs, with the 30 day pack consistent with monthly prescribing. The NHS List Price for the 30 day pack is £4.40, with the 20 day pack priced at £3.65. Acepiro is being launched by Stirling Anglian Pharmaceuticals (SAP), which was acquired by Kelso Pharma one year ago, providing a new UK platform and springboard for future sales growth for the business. The new product complements SAP's existing portfolio of three medicines: CosmoCol (macrogol 3350 plus electrolytes) powder for oral solution - an osmotic laxative indicated for the treatment of chronic constipation and faecal impaction. Stirlescent (naproxen) 250mg effervescent tablets - containing naproxen, which is a non-steroidal anti-inflammatory drug (NSAID).
1 - 7 of 7
Showing 20 items per page